Last earnings -64.9% on 2026-05-06
Conservative balance sheet (liabilities/equity 0.44x).
Revenue (FY2025) $0.00 · FY2025
This call stands until the filings change it — the engine re-rates on new 10-K/10-Q/8-K facts, never on price moves. Hit Watch above to follow RVMDW (Pro alerts fire the moment a rating flips), or catch every change in Saturday’s Flip Side. How to read a call
Revolution Medicines, Inc. shows $0.00 in FY2025 revenue, and -69.3% ROE.
Supporting the case: conservative balance sheet (liabilities/equity 0.44x).
Is RVMDW a buy? The one-page verdict, explained →
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $29.4M | $35.4M | $11.6M | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$188M | -$258M | -$487M | -$690M | -$1.18B |
| Net income | -$187M | -$249M | -$436M | -$600M | -$1.13B |
| Diluted EPS | -$2.57 | -$3.08 | -$3.86 | -$3.58 | -$5.95 |
| Net margin | -636.6% | -703.0% | -3768.3% | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
The daily Brief delivers our freshest calls, rating flips and the filings behind them — every morning, free.
Sources: SEC EDGAR (CIK 0001628171, latest 10-Q filed 2026-05-06) · EODHD · as of 7/15/2026, 7:36:45 PM.
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 15, 2026, 3:36 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Disclosed smart-money activity in RVMDW, but no clear buy consensus.
Different disclosure clocks — Form 4s file within days, Congress PTRs lag up to ~45 days, and 13F holdings are a quarterly snapshot (up to ~4.5 months old). A disclosed-accumulation view, not live correlation.
Last 90 days: 0 open-market buys · 13 sales
| 2026-06-29 | Patel Sushil Director | Exercise | 2.96K @ $37.54 | $111K |
| 2026-06-29 | Patel Sushil Director | Sellplan | 300.00 @ $183.17 | $55.0K |
| 2026-06-29 | Patel Sushil Director | Sellplan | 900.00 @ $184.59 | $166K |
| 2026-06-29 | Patel Sushil Director | Sellplan | 1.10K @ $185.90 | $204K |
| 2026-06-29 | Patel Sushil Director | Sellplan | 858.00 @ $186.92 | $160K |
| 2026-06-29 | Patel Sushil Director | Sellplan | 300.00 @ $187.83 | $56.3K |
| 2026-06-29 | Patel Sushil Director | Sellplan | 100.00 @ $188.57 | $18.9K |
| 2026-06-29 | Patel Sushil Director | Sellplan | 600.00 @ $190.55 | $114K |
| 2026-06-29 | Patel Sushil Director | Sellplan | 541.00 @ $191.87 | $104K |
| 2026-06-29 | Patel Sushil Director | Sellplan | 881.00 @ $192.61 | $170K |
| 2026-06-24 | Anders Jack Chief Financial Officer | Exercise | 20.0K @ $18.56 | $371K |
| 2026-06-24 | Anders Jack Chief Financial Officer | Sellplan | 4.55K @ $167.35 | $762K |
| Sculptor Capital | 959K sh | $1.70M |
As of each fund’s latest quarterly 13F — a delayed snapshot, not a live position. All tracked funds →
No unusual settlement fails — 110 shares failed to deliver on the latest published day.
RVMDW fails-to-deliver history — every published settlement day →
Aggregate CNS settlement fails on the latest published day, vs this name’s trailing median. From SEC fails-to-deliver data (published twice monthly) — a settlement metric, not short interest.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1178 tracked peers · median